<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00703911</url>
  </required_header>
  <id_info>
    <org_study_id>F7HAEM-3507</org_study_id>
    <nct_id>NCT00703911</nct_id>
  </id_info>
  <brief_title>Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors</brief_title>
  <acronym>ONE</acronym>
  <official_title>A Prospective Observational Registry on the Use of NovoSeven® (Activated Recombinant Human Factor VIIa) for on Demand Treatment of Mild to Moderate Bleeds in Haemophilia A and B Patients With Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was conducted in Africa, Europe, the Middle-East and South America. The primary
      objective of this registry was to observe the use of single dose and multi-dose use of
      activated recombinant human factor VII and to compare short-term outcomes, including
      effectiveness, safety, quality of life and treatment satisfaction with the approved
      treatments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Bleed Treatments Resulting in Effective Bleed Resolution (All Bleed Episodes)</measure>
    <time_frame>within 9 hours of first injection</time_frame>
    <description>The percentage of bleed treatments successfully resulting in bleed resolution. Analysis only considers the patient's opinion of effectiveness at 9 hours, with a rating of &quot;Effective&quot; considered as successful treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Bleed Treatments Resulting in Effective Bleed Resolution (Spontaneous Bleed Episodes)</measure>
    <time_frame>within 9 hours of first injection</time_frame>
    <description>The percentage of bleed treatments successfully resulting in bleed resolution. Analysis only considers the patient's opinion of effectiveness at 9 hours, with a rating of &quot;Effective&quot; considered as successful treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Bleed Treatments Resulting in Effective Pain Relief (All Bleed Episodes)</measure>
    <time_frame>within 9 hours of first injection</time_frame>
    <description>The percentage of participants with effective pain relief. Pain relief was a subjective assessment made by the patient during treatment of a bleed episode.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Bleed Treatments Resulting in Effective Pain Relief (Spontaneous Bleed Episodes)</measure>
    <time_frame>within 9 hours of first injection</time_frame>
    <description>The percentage of participants with effective pain relief. Pain relief was a subjective assessment made by the patient during treatment of a bleed episode.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleeds) by Time Point (All Bleed Episodes)</measure>
    <time_frame>1 hour, 3 hours and 6 hours, respectively, after first injection</time_frame>
    <description>Effective haemostasis at 3 different time points for all bleeds. Patient reported outcomes are reported over 1 hour, 3 hours and 6 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleeds) by Time Point (Spontaneous Bleed Episodes)</measure>
    <time_frame>1 hour, 3 hours and 6 hours, respectively, after first injection</time_frame>
    <description>Effective haemostasis at 3 different time points for all bleeds. Patient reported outcomes are reported over 1 hour, 3 hours and 6 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Bleed Treatments Resulting in Effective Pain Relief by Time Point (All Bleed Episodes)</measure>
    <time_frame>1 hour, 3 hours and 6 hours, respectively, after first injection</time_frame>
    <description>Effective pain relief at 3 different time points for all bleeds. Patient reported outcomes are reported over 1 hour, 3 hours and 6 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Bleed Treatments Resulting in Effective Pain Relief by Time Point (Spontaneous Bleed Episodes)</measure>
    <time_frame>1 hour, 3 hours and 6 hours, respectively, after first injection</time_frame>
    <description>Effective pain relief at 3 different time points for spontaneous bleeds. Patient reported outcomes are reported over 1 hour, 3 hours and 6 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Injections (All Bleed Episodes)</measure>
    <time_frame>individual bleed episode</time_frame>
    <description>The median number of injections required to treat individual bleed episodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Injections (Spontaneous Bleed Episodes)</measure>
    <time_frame>individual bleed episode</time_frame>
    <description>The median number of injections required to treat individual bleed episodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Exposure (Cumulative Dose) to Activated Recombinant Human Factor VII (All Bleed Episodes)</measure>
    <time_frame>individual bleed episode</time_frame>
    <description>The median total cumulative dose required to treat individual bleed episodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Exposure (Cumulative Dose) to Activated Recombinant Human Factor VII (Spontaneous Bleed Episodes)</measure>
    <time_frame>individual bleed episode</time_frame>
    <description>The median total cumulative dose required to treat individual bleed episodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Reporting Satisfaction With Symptom Relief (All Bleed Episodes)</measure>
    <time_frame>duration of bleed episode</time_frame>
    <description>Patient rate of satisfaction with symptom relief for the bleed episode overall on a 7-point Likert scale. Completion of questionnaire was voluntary. A Likert scale is an ordered, multiple choice questionnaire from which respondents choose one option that best aligns with their view of the particular outcome being measured. Scale answers ranged from extremely satisfied to extremely dissatisfied. The percentage of bleed episodes for which patients reported &quot;extremely satisfied&quot;, &quot;very satisfied&quot; or &quot;satisfied&quot; is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Bleed Treatments Resulting in Patient Satisfaction With Symptom Relief (Spontaneous Bleed Episodes)</measure>
    <time_frame>duration of bleed episode</time_frame>
    <description>Patient rate of satisfaction with symptom relief for the bleed episode overall on a 7-point Likert scale. Completion of questionnaire was voluntary. A Likert scale is an ordered, multiple choice questionnaire from which respondents choose one option that best aligns with their view of the particular outcome being measured. Scale answers ranged from extremely satisfied to extremely dissatisfied. The percentage of bleed episodes for which patients reported &quot;extremely satisfied&quot;, &quot;very satisfied&quot; or &quot;satisfied&quot; is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Bleed Treatments Resulting in Patient Satisfaction With Ease of Use (All Bleed Episodes)</measure>
    <time_frame>duration of bleed episode</time_frame>
    <description>Rate of ease of use related to activated recombinant human factor VII on a 7-point Likert scale. Completion of questionnaire was voluntary. A Likert scale is an ordered, multiple choice questionnaire from which respondents choose one option that best aligns with their view of the particular outcome being measured. Scale answers ranged from extremely difficult to extremely easy. The percentage of bleed episodes for which patients reported &quot;extremely easy&quot;, &quot;very easy&quot; or &quot;easy&quot; is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Bleed Treatments Resulting in Patient Satisfaction With Ease of Use (Spontaneous Bleed Episodes)</measure>
    <time_frame>duration of bleed episode</time_frame>
    <description>Rate of ease of use related to activated recombinant human factor VII on a 7-point Likert scale. Completion of questionnaire was voluntary. A Likert scale is an ordered, multiple choice questionnaire from which respondents choose one option that best aligns with their view of the particular outcome being measured. Scale answers ranged from extremely difficult to extremely easy. The percentage of bleed episodes for which patients reported &quot;extremely easy&quot;, &quot;very easy&quot; or &quot;easy&quot; is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Time to Cessation of Bleed/Achievement of Haemostasis (All Bleed Episodes)</measure>
    <time_frame>duration of bleed episode</time_frame>
    <description>Median time to achievement of haemostasis/bleed cessation calculated using Kaplan Meier life table methods. If approximately 50% or less of bleeds achieved the endpoint in a given initial dose subgroup, the median cannot be calculated and it is reported as not applicable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Time to Cessation of Bleed/Achievement of Haemostasis (Spontaneous Bleed Episodes)</measure>
    <time_frame>duration of bleed episode</time_frame>
    <description>Median time to achievement of haemostasis/bleed cessation calculated using Kaplan Meier life table methods. If approximately 50% or less of bleeds achieved the endpoint in a given initial dose subgroup, the median cannot be calculated and it is reported as not applicable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Time to Cessation/Achievement of Haemostasis (Spontaneous Bleed Episodes)</measure>
    <time_frame>duration of bleed episode</time_frame>
    <description>Median time to achievement of haemostasis/bleed cessation calculated using Kaplan Meier life table methods. If approximately 50% or less of bleeds achieved the endpoint in a given initial dose subgroup, the median cannot be calculated and it is reported as not applicable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Childrens' Health Related Quality of Life (Haemo-QoL): Overall Score</measure>
    <time_frame>Baseline (week 0) and and registry discontinuation (up to 28 months)</time_frame>
    <description>The Haemo-QoL is a specific multidimensional validated and reliable questionnaire used to assess quality of life in patients with haemophilia. Scores are reported on a 0 to 100 scale—higher scores indicate more impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adults' Health Related Quality of Life (Haemo-QoL-A): Overall Score</measure>
    <time_frame>Baseline (week 0) and and registry discontinuation (up to 28 months)</time_frame>
    <description>The adult Haemo-QoL-A is a specific multidimensional validated and reliable questionnaire used to assess quality of life in patients with haemophilia. Scores are reported on a 0 to 100 scale—higher scores indicate more impairment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleed) by Dose Level (All Bleed Episodes)</measure>
    <time_frame>within 9 hours after first injection</time_frame>
    <description>Percentage of bleeds with effective haemostasis within 9 hours of first injection of activated recombinant human factor VII. Patient reported assessments were sorted into 3 sub-categories: &quot;effective&quot; = bleed resolved or substantially improved; &quot;partially effective&quot; = bleed with some improvement; &quot;ineffective&quot; = bleed with no change or with worsening.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleed) by Dose Level (Spontaneous Bleed Episodes)</measure>
    <time_frame>within 9 hours after first injection</time_frame>
    <description>Percentage of bleeds with effective haemostasis within 9 hours of first injection of activated recombinant human factor VII. Patient reported assessments were sorted into 3 sub-categories: &quot;effective&quot; = bleed resolved or substantially improved; &quot;partially effective&quot; = bleed with some improvement; &quot;ineffective&quot; = bleed with no change or with worsening.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Bleed Treatments Resulting in Effective Pain Relief by Initial Dose (All Bleed Episodes)</measure>
    <time_frame>within 9 hours after first injection</time_frame>
    <description>Percentage of bleeds with effective pain relief within 9 hours of first injection of activated recombinant human factor VII. Patient reported assessments were sorted into 3 sub-categories: &quot;Better&quot; = pain resolved or decreased substantially; &quot;Same&quot; = no change; &quot;Worsened&quot; = pain worsening.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Bleed Treatments Resulting in Effective Pain Relief by Initial Dose (Spontaneous Bleed Episodes)</measure>
    <time_frame>within 9 hours after first injection</time_frame>
    <description>Percentage of bleeds with effective pain relief within 9 hours of first injection of activated recombinant human factor VII. Patient reported assessments were sorted into 3 sub-categories: &quot;Better&quot; = pain resolved or decreased substantially; &quot;Same&quot; = no change; &quot;Worsened&quot; = pain worsening.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">102</enrollment>
  <condition>Congenital Bleeding Disorder</condition>
  <condition>Haemophilia A With Inhibitors</condition>
  <condition>Haemophilia B With Inhibitors</condition>
  <arm_group>
    <arm_group_label>activated recombinant human factor VII</arm_group_label>
    <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eptacog alfa (activated)</intervention_name>
    <description>Treatment of patients experiencing bleeds at the discretion of the physician/caregiver</description>
    <arm_group_label>activated recombinant human factor VII</arm_group_label>
    <other_name>activated recombinant human factor VII</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with haemophilia A or B with inhibitors, using activated recombinant human factor
        VII as on-demand treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with haemophilia A or B with inhibitors

          -  Experience mild to moderate spontaneous bleeds which require on-demand treatment and
             who are currently prescribed activated recombinant human factor VII

          -  Be able and willing to provide informed consent (or proxy consent by caregiver, if
             applicable), as required by local research ethics committee, governmental or
             regulatory authorities

          -  Be willing to provide information on at least one alternate contact person in the
             event that the patient be somehow lost-to-follow-up over the course of registry
             participation (not applicable if patient is withdrawn)

        Exclusion Criteria:

          -  Known hypersensitivity to the active substance or the excipients in the formulation of
             activated recombinant human factor VII, or to mouse, hamster or bovine protein
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Algiers</city>
        <zip>16035</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Vienna</city>
        <zip>A-1010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Prague</city>
        <zip>16000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Paris La défense cedex</city>
        <zip>92932</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mainz</city>
        <zip>55127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Alphen a/d Rijn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>PL-02-274</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Paco de Arcos</city>
        <zip>2780-730</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Riyadh</city>
        <zip>3542</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sandton</city>
        <zip>2146</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Malmö</city>
        <zip>202 15</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34335</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Crawley</city>
        <zip>RH11 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Caracas</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Algeria</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Saudi Arabia</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>Venezuela</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>Costa Rica</country>
    <country>Hungary</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2008</study_first_submitted>
  <study_first_submitted_qc>June 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2008</study_first_posted>
  <results_first_submitted>July 29, 2011</results_first_submitted>
  <results_first_submitted_qc>November 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2011</results_first_posted>
  <last_update_submitted>November 22, 2016</last_update_submitted>
  <last_update_submitted_qc>November 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Activated Recombinant Human Factor VII</title>
          <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Activated Recombinant Human Factor VII</title>
          <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.3" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>2 - 12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>above 12 - 17 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 years or above</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Algeria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Saudi Arabia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Venezuela</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peak inhibitor titre</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>At least 5 Bethesda Units</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Less than 5 Bethesda Units</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Outcome of immune tolerance induction (ITI) treatment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsuccessful</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Successful, with inhibitor recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ongoing ITI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated number of bleeds for the 6 months preceding enrolment in registry</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 - 6 (1 or less per month)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 - 12 (1 - 2 per month)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 - 18 (2 - 3 per month)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 (more than 3 per month)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary treatment pattern for the 6 months preceding enrolment in registry</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>On-demand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prophylaxis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary treatment type and dose for the 6 months preceding enrolment in registry</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Multiple dose 90 mcg/kg NovoSeven®</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Single dose 270 mcg/kg NovoSeven®</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other dose regimen NovoSeven®</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other bypassing agent (e.g., FEIBA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Bleed Treatments Resulting in Effective Bleed Resolution (All Bleed Episodes)</title>
        <description>The percentage of bleed treatments successfully resulting in bleed resolution. Analysis only considers the patient's opinion of effectiveness at 9 hours, with a rating of &quot;Effective&quot; considered as successful treatment.</description>
        <time_frame>within 9 hours of first injection</time_frame>
        <population>Analysis set is all bleed episodes, regardless of bleed type or initial dose level</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Bleed Treatments Resulting in Effective Bleed Resolution (All Bleed Episodes)</title>
          <description>The percentage of bleed treatments successfully resulting in bleed resolution. Analysis only considers the patient's opinion of effectiveness at 9 hours, with a rating of &quot;Effective&quot; considered as successful treatment.</description>
          <population>Analysis set is all bleed episodes, regardless of bleed type or initial dose level</population>
          <units>percentage of bleed episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any initial dose, n=494</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low initial dose, n=156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate initial dose, n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High initial dose, n=211</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Bleed Treatments Resulting in Effective Bleed Resolution (Spontaneous Bleed Episodes)</title>
        <description>The percentage of bleed treatments successfully resulting in bleed resolution. Analysis only considers the patient's opinion of effectiveness at 9 hours, with a rating of &quot;Effective&quot; considered as successful treatment.</description>
        <time_frame>within 9 hours of first injection</time_frame>
        <population>Analysis set is spontaneous bleed episodes treated with any initial dose</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Bleed Treatments Resulting in Effective Bleed Resolution (Spontaneous Bleed Episodes)</title>
          <description>The percentage of bleed treatments successfully resulting in bleed resolution. Analysis only considers the patient's opinion of effectiveness at 9 hours, with a rating of &quot;Effective&quot; considered as successful treatment.</description>
          <population>Analysis set is spontaneous bleed episodes treated with any initial dose</population>
          <units>percentage of bleed episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any initial dose, n=324</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low initial dose, n=92</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate initial dose, n=91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High initial dose, n=141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Bleed Treatments Resulting in Effective Pain Relief (All Bleed Episodes)</title>
        <description>The percentage of participants with effective pain relief. Pain relief was a subjective assessment made by the patient during treatment of a bleed episode.</description>
        <time_frame>within 9 hours of first injection</time_frame>
        <population>Analysis set is all bleed episodes, regardless of bleed type or initial dose level</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Bleed Treatments Resulting in Effective Pain Relief (All Bleed Episodes)</title>
          <description>The percentage of participants with effective pain relief. Pain relief was a subjective assessment made by the patient during treatment of a bleed episode.</description>
          <population>Analysis set is all bleed episodes, regardless of bleed type or initial dose level</population>
          <units>percentage of bleed episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any initial dose, n=494</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low initial dose, n=156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate initial dose, n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High initial dose, n=211</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Bleed Treatments Resulting in Effective Pain Relief (Spontaneous Bleed Episodes)</title>
        <description>The percentage of participants with effective pain relief. Pain relief was a subjective assessment made by the patient during treatment of a bleed episode.</description>
        <time_frame>within 9 hours of first injection</time_frame>
        <population>Analysis set is spontaneous bleed episodes treated with any initial dose</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Bleed Treatments Resulting in Effective Pain Relief (Spontaneous Bleed Episodes)</title>
          <description>The percentage of participants with effective pain relief. Pain relief was a subjective assessment made by the patient during treatment of a bleed episode.</description>
          <population>Analysis set is spontaneous bleed episodes treated with any initial dose</population>
          <units>percentage of bleed episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any initial dose, n=324</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low initial dose, n=92</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate initial dose, n=91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High initial dose, n=141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleeds) by Time Point (All Bleed Episodes)</title>
        <description>Effective haemostasis at 3 different time points for all bleeds. Patient reported outcomes are reported over 1 hour, 3 hours and 6 hours.</description>
        <time_frame>1 hour, 3 hours and 6 hours, respectively, after first injection</time_frame>
        <population>Analysis set is all bleed episodes, regardless of bleed type or initial dose level</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleeds) by Time Point (All Bleed Episodes)</title>
          <description>Effective haemostasis at 3 different time points for all bleeds. Patient reported outcomes are reported over 1 hour, 3 hours and 6 hours.</description>
          <population>Analysis set is all bleed episodes, regardless of bleed type or initial dose level</population>
          <units>percentage of bleed episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any initial dose (1 hour), n=494</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low initial dose (1 hour), n=156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate initial dose (1 hr), n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High initial dose (1 hour), n=211</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any initial dose (3 hours), n=494</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low initial dose (3 hours), n=156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate initial dose (3 hrs), n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High initial dose (3 hours), n=211</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any initial dose (6 hours), n=494</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low initial dose (6 hours), n=156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate initial dose (6 hrs), n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High initial dose (6 hours), n=211</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleeds) by Time Point (Spontaneous Bleed Episodes)</title>
        <description>Effective haemostasis at 3 different time points for all bleeds. Patient reported outcomes are reported over 1 hour, 3 hours and 6 hours.</description>
        <time_frame>1 hour, 3 hours and 6 hours, respectively, after first injection</time_frame>
        <population>Analysis set is spontaneous bleed episodes treated with any initial dose</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleeds) by Time Point (Spontaneous Bleed Episodes)</title>
          <description>Effective haemostasis at 3 different time points for all bleeds. Patient reported outcomes are reported over 1 hour, 3 hours and 6 hours.</description>
          <population>Analysis set is spontaneous bleed episodes treated with any initial dose</population>
          <units>percentage of bleed episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any initial dose (1 hour), n=324</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low initial dose (1 hour), n=92</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate initial dose (1 hr), n=91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High initial dose (1 hour), n=141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any initial dose (3 hours), n=324</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low initial dose (3 hours), n=92</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate initial dose (3 hrs), n=91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High initial dose (3 hours), n=141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any initial dose (6 hours), n=324</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low initial dose (6 hours), n=92</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate initial dose (6 hrs), n=91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High initial dose (6 hours), n=141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Bleed Treatments Resulting in Effective Pain Relief by Time Point (All Bleed Episodes)</title>
        <description>Effective pain relief at 3 different time points for all bleeds. Patient reported outcomes are reported over 1 hour, 3 hours and 6 hours.</description>
        <time_frame>1 hour, 3 hours and 6 hours, respectively, after first injection</time_frame>
        <population>Analysis set is all bleed episodes, regardless of bleed type or initial dose level</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Bleed Treatments Resulting in Effective Pain Relief by Time Point (All Bleed Episodes)</title>
          <description>Effective pain relief at 3 different time points for all bleeds. Patient reported outcomes are reported over 1 hour, 3 hours and 6 hours.</description>
          <population>Analysis set is all bleed episodes, regardless of bleed type or initial dose level</population>
          <units>percentage of bleed episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any initial dose (1 hour), n=494</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low initial dose (1 hour), n=156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate initial dose (1 hr), n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High initial dose (1 hour), n=211</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any initial dose (3 hours), n=494</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low initial dose (3 hours), n=156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate initial dose (3 hrs), n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High initial dose (3 hours), n=211</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any initial dose (6 hours), n=494</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low initial dose (6 hours), n=156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate initial dose (6 hrs), n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High initial dose (6 hours), n=211</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Bleed Treatments Resulting in Effective Pain Relief by Time Point (Spontaneous Bleed Episodes)</title>
        <description>Effective pain relief at 3 different time points for spontaneous bleeds. Patient reported outcomes are reported over 1 hour, 3 hours and 6 hours.</description>
        <time_frame>1 hour, 3 hours and 6 hours, respectively, after first injection</time_frame>
        <population>Analysis set is spontaneous bleed episodes treated with any initial dose</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Bleed Treatments Resulting in Effective Pain Relief by Time Point (Spontaneous Bleed Episodes)</title>
          <description>Effective pain relief at 3 different time points for spontaneous bleeds. Patient reported outcomes are reported over 1 hour, 3 hours and 6 hours.</description>
          <population>Analysis set is spontaneous bleed episodes treated with any initial dose</population>
          <units>percentage of bleed episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any initial dose (1 hour), n=324</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low initial dose (1 hour), n=92</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate initial dose (1 hr), n=91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High initial dose (1 hour), n=141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any initial dose (3 hours), n=324</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low initial dose (3 hours), n=92</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate initial dose (3 hrs), n=91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High initial dose (3 hours), n=141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any initial dose (6 hours), n=324</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low initial dose (6 hours), n=92</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate initial dose (6 hrs), n=91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High initial dose (6 hours), n=141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Injections (All Bleed Episodes)</title>
        <description>The median number of injections required to treat individual bleed episodes.</description>
        <time_frame>individual bleed episode</time_frame>
        <population>Analysis set is all bleed episodes, regardless of bleed type or initial dose level</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Injections (All Bleed Episodes)</title>
          <description>The median number of injections required to treat individual bleed episodes.</description>
          <population>Analysis set is all bleed episodes, regardless of bleed type or initial dose level</population>
          <units>injections</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any initial dose, n=494</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low dose, n=156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="2" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate dose, n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High dose, n=211</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Injections (Spontaneous Bleed Episodes)</title>
        <description>The median number of injections required to treat individual bleed episodes.</description>
        <time_frame>individual bleed episode</time_frame>
        <population>Analysis set is spontaneous bleed episodes treated with any initial dose</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Injections (Spontaneous Bleed Episodes)</title>
          <description>The median number of injections required to treat individual bleed episodes.</description>
          <population>Analysis set is spontaneous bleed episodes treated with any initial dose</population>
          <units>injections</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any initial dose, n=324</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low dose, n=92</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="2" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate dose, n=91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High dose, n=141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Exposure (Cumulative Dose) to Activated Recombinant Human Factor VII (All Bleed Episodes)</title>
        <description>The median total cumulative dose required to treat individual bleed episodes.</description>
        <time_frame>individual bleed episode</time_frame>
        <population>Analysis set is all bleed episodes, regardless of bleed type or initial dose level. Excludes bleeds episodes with greater than 24 hours between 1st and 2nd rFVII dose where total cumulative dose recorded likely reflects treatment of re-bleeding or prophylactic/maintenance dosing</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Total Exposure (Cumulative Dose) to Activated Recombinant Human Factor VII (All Bleed Episodes)</title>
          <description>The median total cumulative dose required to treat individual bleed episodes.</description>
          <population>Analysis set is all bleed episodes, regardless of bleed type or initial dose level. Excludes bleeds episodes with greater than 24 hours between 1st and 2nd rFVII dose where total cumulative dose recorded likely reflects treatment of re-bleeding or prophylactic/maintenance dosing</population>
          <units>mcg/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any initial dose, n=494</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270" lower_limit="43" upper_limit="2160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low dose, n=156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267" lower_limit="43" upper_limit="1632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate dose, n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="256" lower_limit="123" upper_limit="2160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High dose, n=211</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270" lower_limit="250" upper_limit="1822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Exposure (Cumulative Dose) to Activated Recombinant Human Factor VII (Spontaneous Bleed Episodes)</title>
        <description>The median total cumulative dose required to treat individual bleed episodes.</description>
        <time_frame>individual bleed episode</time_frame>
        <population>Analysis set is spontaneous bleed episodes. Excludes bleeds episodes with &gt; 24 hours between 1st and 2nd rFVII dose where total cumulative dose recorded likely reflects treatment of re-bleeding or prophylactic/maintenance dosing, and 2 bleed episodes categorised as CNS that would not meet criteria of mild to moderate spontaneous bleed episodes</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Total Exposure (Cumulative Dose) to Activated Recombinant Human Factor VII (Spontaneous Bleed Episodes)</title>
          <description>The median total cumulative dose required to treat individual bleed episodes.</description>
          <population>Analysis set is spontaneous bleed episodes. Excludes bleeds episodes with &gt; 24 hours between 1st and 2nd rFVII dose where total cumulative dose recorded likely reflects treatment of re-bleeding or prophylactic/maintenance dosing, and 2 bleed episodes categorised as CNS that would not meet criteria of mild to moderate spontaneous bleed episodes</population>
          <units>mcg/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any initial dose, n=324</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184" lower_limit="90" upper_limit="1632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low dose, n=92</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284" lower_limit="123" upper_limit="2160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate dose, n=91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270" lower_limit="250" upper_limit="1822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High dose, n=141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270" lower_limit="90" upper_limit="2160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Reporting Satisfaction With Symptom Relief (All Bleed Episodes)</title>
        <description>Patient rate of satisfaction with symptom relief for the bleed episode overall on a 7-point Likert scale. Completion of questionnaire was voluntary. A Likert scale is an ordered, multiple choice questionnaire from which respondents choose one option that best aligns with their view of the particular outcome being measured. Scale answers ranged from extremely satisfied to extremely dissatisfied. The percentage of bleed episodes for which patients reported &quot;extremely satisfied&quot;, &quot;very satisfied&quot; or &quot;satisfied&quot; is presented.</description>
        <time_frame>duration of bleed episode</time_frame>
        <population>Analysis set is all bleed episodes, regardless of bleed type or initial dose level</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Reporting Satisfaction With Symptom Relief (All Bleed Episodes)</title>
          <description>Patient rate of satisfaction with symptom relief for the bleed episode overall on a 7-point Likert scale. Completion of questionnaire was voluntary. A Likert scale is an ordered, multiple choice questionnaire from which respondents choose one option that best aligns with their view of the particular outcome being measured. Scale answers ranged from extremely satisfied to extremely dissatisfied. The percentage of bleed episodes for which patients reported &quot;extremely satisfied&quot;, &quot;very satisfied&quot; or &quot;satisfied&quot; is presented.</description>
          <population>Analysis set is all bleed episodes, regardless of bleed type or initial dose level</population>
          <units>percentage of bleed episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any dose, n=494</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low dose, n=156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate dose, n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High dose, n=211</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Bleed Treatments Resulting in Patient Satisfaction With Symptom Relief (Spontaneous Bleed Episodes)</title>
        <description>Patient rate of satisfaction with symptom relief for the bleed episode overall on a 7-point Likert scale. Completion of questionnaire was voluntary. A Likert scale is an ordered, multiple choice questionnaire from which respondents choose one option that best aligns with their view of the particular outcome being measured. Scale answers ranged from extremely satisfied to extremely dissatisfied. The percentage of bleed episodes for which patients reported &quot;extremely satisfied&quot;, &quot;very satisfied&quot; or &quot;satisfied&quot; is presented.</description>
        <time_frame>duration of bleed episode</time_frame>
        <population>Analysis set is spontaneous bleed episodes treated with any initial dose</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Bleed Treatments Resulting in Patient Satisfaction With Symptom Relief (Spontaneous Bleed Episodes)</title>
          <description>Patient rate of satisfaction with symptom relief for the bleed episode overall on a 7-point Likert scale. Completion of questionnaire was voluntary. A Likert scale is an ordered, multiple choice questionnaire from which respondents choose one option that best aligns with their view of the particular outcome being measured. Scale answers ranged from extremely satisfied to extremely dissatisfied. The percentage of bleed episodes for which patients reported &quot;extremely satisfied&quot;, &quot;very satisfied&quot; or &quot;satisfied&quot; is presented.</description>
          <population>Analysis set is spontaneous bleed episodes treated with any initial dose</population>
          <units>percentage of bleed episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any dose, n=324</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low dose, n=92</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate dose, n=91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High dose, n=141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Bleed Treatments Resulting in Patient Satisfaction With Ease of Use (All Bleed Episodes)</title>
        <description>Rate of ease of use related to activated recombinant human factor VII on a 7-point Likert scale. Completion of questionnaire was voluntary. A Likert scale is an ordered, multiple choice questionnaire from which respondents choose one option that best aligns with their view of the particular outcome being measured. Scale answers ranged from extremely difficult to extremely easy. The percentage of bleed episodes for which patients reported &quot;extremely easy&quot;, &quot;very easy&quot; or &quot;easy&quot; is presented.</description>
        <time_frame>duration of bleed episode</time_frame>
        <population>Analysis set is all bleed episodes, regardless of bleed type or initial dose level</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Bleed Treatments Resulting in Patient Satisfaction With Ease of Use (All Bleed Episodes)</title>
          <description>Rate of ease of use related to activated recombinant human factor VII on a 7-point Likert scale. Completion of questionnaire was voluntary. A Likert scale is an ordered, multiple choice questionnaire from which respondents choose one option that best aligns with their view of the particular outcome being measured. Scale answers ranged from extremely difficult to extremely easy. The percentage of bleed episodes for which patients reported &quot;extremely easy&quot;, &quot;very easy&quot; or &quot;easy&quot; is presented.</description>
          <population>Analysis set is all bleed episodes, regardless of bleed type or initial dose level</population>
          <units>percentage of bleed episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any dose, n=494</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low dose, n=156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate dose, n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High dose, n=211</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Bleed Treatments Resulting in Patient Satisfaction With Ease of Use (Spontaneous Bleed Episodes)</title>
        <description>Rate of ease of use related to activated recombinant human factor VII on a 7-point Likert scale. Completion of questionnaire was voluntary. A Likert scale is an ordered, multiple choice questionnaire from which respondents choose one option that best aligns with their view of the particular outcome being measured. Scale answers ranged from extremely difficult to extremely easy. The percentage of bleed episodes for which patients reported &quot;extremely easy&quot;, &quot;very easy&quot; or &quot;easy&quot; is presented.</description>
        <time_frame>duration of bleed episode</time_frame>
        <population>Analysis set is spontaneous bleed episodes treated with any initial dose</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Bleed Treatments Resulting in Patient Satisfaction With Ease of Use (Spontaneous Bleed Episodes)</title>
          <description>Rate of ease of use related to activated recombinant human factor VII on a 7-point Likert scale. Completion of questionnaire was voluntary. A Likert scale is an ordered, multiple choice questionnaire from which respondents choose one option that best aligns with their view of the particular outcome being measured. Scale answers ranged from extremely difficult to extremely easy. The percentage of bleed episodes for which patients reported &quot;extremely easy&quot;, &quot;very easy&quot; or &quot;easy&quot; is presented.</description>
          <population>Analysis set is spontaneous bleed episodes treated with any initial dose</population>
          <units>percentage of bleed episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any dose, n=324</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low dose, n=92</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate dose, n=91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High dose, n=141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Time to Cessation of Bleed/Achievement of Haemostasis (All Bleed Episodes)</title>
        <description>Median time to achievement of haemostasis/bleed cessation calculated using Kaplan Meier life table methods. If approximately 50% or less of bleeds achieved the endpoint in a given initial dose subgroup, the median cannot be calculated and it is reported as not applicable</description>
        <time_frame>duration of bleed episode</time_frame>
        <population>Analysis set is all bleed episodes, regardless of bleed type or initial dose level</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Time to Cessation of Bleed/Achievement of Haemostasis (All Bleed Episodes)</title>
          <description>Median time to achievement of haemostasis/bleed cessation calculated using Kaplan Meier life table methods. If approximately 50% or less of bleeds achieved the endpoint in a given initial dose subgroup, the median cannot be calculated and it is reported as not applicable</description>
          <population>Analysis set is all bleed episodes, regardless of bleed type or initial dose level</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any dose, n=494</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1200" lower_limit="720">Using Kaplan-Meier methods to calculate the median time to event takes into account the censoring of data at the upper part of the distribution. If the upper limit falls to the right of the censoring time, then it will be missing</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low dose, n=156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="720" lower_limit="540" upper_limit="1430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate dose, n=127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Since 50% or less of bleeds achieved the endpoint in the intermediate dose subgroup, the median cannot be calculated and it is reported as &quot;not applicable&quot; (NA)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High dose, n=211</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1200" lower_limit="660">Using Kaplan-Meier methods to calculate the median time to event takes into account the censoring of data at the upper part of the distribution. If the upper limit falls to the right of the censoring time, then it will be missing</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Time to Cessation of Bleed/Achievement of Haemostasis (Spontaneous Bleed Episodes)</title>
        <description>Median time to achievement of haemostasis/bleed cessation calculated using Kaplan Meier life table methods. If approximately 50% or less of bleeds achieved the endpoint in a given initial dose subgroup, the median cannot be calculated and it is reported as not applicable</description>
        <time_frame>duration of bleed episode</time_frame>
        <population>Analysis set is spontaneous bleed episodes treated with any initial dose</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Time to Cessation of Bleed/Achievement of Haemostasis (Spontaneous Bleed Episodes)</title>
          <description>Median time to achievement of haemostasis/bleed cessation calculated using Kaplan Meier life table methods. If approximately 50% or less of bleeds achieved the endpoint in a given initial dose subgroup, the median cannot be calculated and it is reported as not applicable</description>
          <population>Analysis set is spontaneous bleed episodes treated with any initial dose</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any dose, n=324</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1200" lower_limit="600">Using Kaplan-Meier methods to calculate the median time to event takes into account the censoring of data at the upper part of the distribution. If the upper limit falls to the right of the censoring time, then it will be missing</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low dose, n=92</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="600" lower_limit="540">Using Kaplan-Meier methods to calculate the median time to event takes into account the censoring of data at the upper part of the distribution. If the upper limit falls to the right of the censoring time, then it will be missing</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate dose, n=91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Since 50% or less of bleeds achieved the endpoint in the intermediate dose subgroup, the median cannot be calculated and it is reported as &quot;not applicable&quot; (NA)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High dose, n=141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1200" lower_limit="540">Using Kaplan-Meier methods to calculate the median time to event takes into account the censoring of data at the upper part of the distribution. If the upper limit falls to the right of the censoring time, then it will be missing</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Time to Cessation/Achievement of Haemostasis (Spontaneous Bleed Episodes)</title>
        <description>Median time to achievement of haemostasis/bleed cessation calculated using Kaplan Meier life table methods. If approximately 50% or less of bleeds achieved the endpoint in a given initial dose subgroup, the median cannot be calculated and it is reported as not applicable.</description>
        <time_frame>duration of bleed episode</time_frame>
        <population>Analysis set is spontaneous bleed episodes treated with any initial dose, excluding bleed episodes treated with more than one dose for which &gt; 24 hours between the 1st and 2nd dose was reported (bleed episodes with &gt; 24 hours between 1st and 2nd rFVIIa dose likely reflects treatment of re-bleeding or prophylactic/maintenance dosing)</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Time to Cessation/Achievement of Haemostasis (Spontaneous Bleed Episodes)</title>
          <description>Median time to achievement of haemostasis/bleed cessation calculated using Kaplan Meier life table methods. If approximately 50% or less of bleeds achieved the endpoint in a given initial dose subgroup, the median cannot be calculated and it is reported as not applicable.</description>
          <population>Analysis set is spontaneous bleed episodes treated with any initial dose, excluding bleed episodes treated with more than one dose for which &gt; 24 hours between the 1st and 2nd dose was reported (bleed episodes with &gt; 24 hours between 1st and 2nd rFVIIa dose likely reflects treatment of re-bleeding or prophylactic/maintenance dosing)</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any dose, n=270</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="600" lower_limit="480" upper_limit="780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low dose, n=87</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="600" lower_limit="540">Using Kaplan-Meier methods to calculate the median time to event takes into account the censoring of data at the upper part of the distribution. If the upper limit falls to the right of the censoring time, then it will be missing</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate dose, n=80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Since 50% or less of bleeds achieved the endpoint in the intermediate dose subgroup, the median cannot be calculated and it is reported as &quot;not applicable&quot; (NA)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High dose, n=103</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="480" lower_limit="330" upper_limit="720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Childrens' Health Related Quality of Life (Haemo-QoL): Overall Score</title>
        <description>The Haemo-QoL is a specific multidimensional validated and reliable questionnaire used to assess quality of life in patients with haemophilia. Scores are reported on a 0 to 100 scale—higher scores indicate more impairment.</description>
        <time_frame>Baseline (week 0) and and registry discontinuation (up to 28 months)</time_frame>
        <population>A subset of paediatric subjects age 4 to 16 (inclusive) included in the study that completed the questionnaire at baseline and/or at discontinuation</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Childrens' Health Related Quality of Life (Haemo-QoL): Overall Score</title>
          <description>The Haemo-QoL is a specific multidimensional validated and reliable questionnaire used to assess quality of life in patients with haemophilia. Scores are reported on a 0 to 100 scale—higher scores indicate more impairment.</description>
          <population>A subset of paediatric subjects age 4 to 16 (inclusive) included in the study that completed the questionnaire at baseline and/or at discontinuation</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, n=7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.49" spread="11.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation, n=7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.12" spread="10.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adults' Health Related Quality of Life (Haemo-QoL-A): Overall Score</title>
        <description>The adult Haemo-QoL-A is a specific multidimensional validated and reliable questionnaire used to assess quality of life in patients with haemophilia. Scores are reported on a 0 to 100 scale—higher scores indicate more impairment.</description>
        <time_frame>Baseline (week 0) and and registry discontinuation (up to 28 months)</time_frame>
        <population>A subset of adult subjects above 16 years included in the study that completed the questionnaire at baseline and/or at discontinuation</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Adults' Health Related Quality of Life (Haemo-QoL-A): Overall Score</title>
          <description>The adult Haemo-QoL-A is a specific multidimensional validated and reliable questionnaire used to assess quality of life in patients with haemophilia. Scores are reported on a 0 to 100 scale—higher scores indicate more impairment.</description>
          <population>A subset of adult subjects above 16 years included in the study that completed the questionnaire at baseline and/or at discontinuation</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, n=11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.31" spread="9.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation, n=10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.46" spread="12.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleed) by Dose Level (All Bleed Episodes)</title>
        <description>Percentage of bleeds with effective haemostasis within 9 hours of first injection of activated recombinant human factor VII. Patient reported assessments were sorted into 3 sub-categories: &quot;effective&quot; = bleed resolved or substantially improved; &quot;partially effective&quot; = bleed with some improvement; &quot;ineffective&quot; = bleed with no change or with worsening.</description>
        <time_frame>within 9 hours after first injection</time_frame>
        <population>Analysis set is all bleed episodes, regardless of bleed type or initial dose level</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleed) by Dose Level (All Bleed Episodes)</title>
          <description>Percentage of bleeds with effective haemostasis within 9 hours of first injection of activated recombinant human factor VII. Patient reported assessments were sorted into 3 sub-categories: &quot;effective&quot; = bleed resolved or substantially improved; &quot;partially effective&quot; = bleed with some improvement; &quot;ineffective&quot; = bleed with no change or with worsening.</description>
          <population>Analysis set is all bleed episodes, regardless of bleed type or initial dose level</population>
          <units>percentage of bleed episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any, effective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any, partially effective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any, ineffective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low, effective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low, partially effective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low, ineffective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate, effective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate, partially effective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate, ineffective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High, effective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High, partially effective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High, ineffective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleed) by Dose Level (Spontaneous Bleed Episodes)</title>
        <description>Percentage of bleeds with effective haemostasis within 9 hours of first injection of activated recombinant human factor VII. Patient reported assessments were sorted into 3 sub-categories: &quot;effective&quot; = bleed resolved or substantially improved; &quot;partially effective&quot; = bleed with some improvement; &quot;ineffective&quot; = bleed with no change or with worsening.</description>
        <time_frame>within 9 hours after first injection</time_frame>
        <population>Analysis set is spontaneous bleed episodes treated with any initial dose</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Bleed Treatments Resulting in Effective Haemostasis (Cessation of Bleed) by Dose Level (Spontaneous Bleed Episodes)</title>
          <description>Percentage of bleeds with effective haemostasis within 9 hours of first injection of activated recombinant human factor VII. Patient reported assessments were sorted into 3 sub-categories: &quot;effective&quot; = bleed resolved or substantially improved; &quot;partially effective&quot; = bleed with some improvement; &quot;ineffective&quot; = bleed with no change or with worsening.</description>
          <population>Analysis set is spontaneous bleed episodes treated with any initial dose</population>
          <units>percentage of bleed episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any, effective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any, partially effective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any, ineffective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low, effective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low, partially effective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low, ineffective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate, effective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate, partially effective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate, ineffective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High, effective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High, partially effective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High, ineffective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Bleed Treatments Resulting in Effective Pain Relief by Initial Dose (All Bleed Episodes)</title>
        <description>Percentage of bleeds with effective pain relief within 9 hours of first injection of activated recombinant human factor VII. Patient reported assessments were sorted into 3 sub-categories: &quot;Better&quot; = pain resolved or decreased substantially; &quot;Same&quot; = no change; &quot;Worsened&quot; = pain worsening.</description>
        <time_frame>within 9 hours after first injection</time_frame>
        <population>Analysis set is all bleed episodes, regardless of bleed type or initial dose level</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Bleed Treatments Resulting in Effective Pain Relief by Initial Dose (All Bleed Episodes)</title>
          <description>Percentage of bleeds with effective pain relief within 9 hours of first injection of activated recombinant human factor VII. Patient reported assessments were sorted into 3 sub-categories: &quot;Better&quot; = pain resolved or decreased substantially; &quot;Same&quot; = no change; &quot;Worsened&quot; = pain worsening.</description>
          <population>Analysis set is all bleed episodes, regardless of bleed type or initial dose level</population>
          <units>percentage of bleed episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any, better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any, same</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any, worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low, better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low, same</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low, worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate, better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate, same</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate, worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High, better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High, same</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High, worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Bleed Treatments Resulting in Effective Pain Relief by Initial Dose (Spontaneous Bleed Episodes)</title>
        <description>Percentage of bleeds with effective pain relief within 9 hours of first injection of activated recombinant human factor VII. Patient reported assessments were sorted into 3 sub-categories: &quot;Better&quot; = pain resolved or decreased substantially; &quot;Same&quot; = no change; &quot;Worsened&quot; = pain worsening.</description>
        <time_frame>within 9 hours after first injection</time_frame>
        <population>Analysis set is spontaneous bleed episodes treated with any initial dose</population>
        <group_list>
          <group group_id="O1">
            <title>Activated Recombinant Human Factor VII</title>
            <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Bleed Treatments Resulting in Effective Pain Relief by Initial Dose (Spontaneous Bleed Episodes)</title>
          <description>Percentage of bleeds with effective pain relief within 9 hours of first injection of activated recombinant human factor VII. Patient reported assessments were sorted into 3 sub-categories: &quot;Better&quot; = pain resolved or decreased substantially; &quot;Same&quot; = no change; &quot;Worsened&quot; = pain worsening.</description>
          <population>Analysis set is spontaneous bleed episodes treated with any initial dose</population>
          <units>percentage of bleed episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any, better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any, same</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any, worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low, better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low, same</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low, worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate, better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate, same</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate, worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High, better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High, same</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High, worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Activated Recombinant Human Factor VII</title>
          <description>Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to Novo Nordisk for review at least 60 days before submission for publication or presentation. The investigator will recognize the integrity of a multi-centre study by not publishing data derived from the individual site until the combined results from the completed registry have been published in full, or the sponsor confirms there will be no multi-centre registry publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Public Access to Clinical Trials</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

